Sugi Predict

Sugi Predict / Compounds / SCHEMBL3147129

SCHEMBL3147129

SCHEMBL3147129

O=C1CCCCc2sccc21

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ USP2 O75604 1/20 0.52
▸ NOS2 P35228 1/20 0.39
▸ CES1 P23141 1/20 0.39
▸ MAOA P21397 2/20 0.39
▸ MAOB P27338 2/20 0.39
▸ CYP2A6 P11509 1/20 0.39
▸ PLK4 O00444 1/20 0.35
▸ CHEK1 O14757 1/20 0.35
▸ AURKA O14965 1/20 0.35
▸ DAPK3 O43293 1/20 0.35
▸ PRKD3 O94806 1/20 0.35
▸ MAP4K4 O95819 1/20 0.35
▸ PAK4 O96013 1/20 0.35
▸ PIM1 P11309 1/20 0.35
▸ PDGFRA P16234 1/20 0.35
▸ PRKACA P17612 1/20 0.35
▸ LTK P29376 1/20 0.35
▸ GRK5 P34947 1/20 0.35
▸ KDR P35968 1/20 0.35
▸ MAP2K2 P36507 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23426452 1.00 USP2 (0.52) USP2NOS2CES1MAOAMAOB
SCHEMBL153954 0.95 USP2 (0.47) USP2NOS2CES1MAOAMAOB
SCHEMBL1747122 0.86 — —
SCHEMBL16663983 0.78 MAOA (0.41) USP2MAOAMAOBCYP2A6PLK3
SCHEMBL208564 0.75 USP2 (0.50) USP2NOS2CES1PLK4CHEK1
SCHEMBL9038503 0.74 USP2 (0.44) USP2NOS2PLK4CHEK1AURKA
SCHEMBL15219995 0.73 CES1 (0.50) USP2NOS2CES1MAOAPLK4
SCHEMBL17225453 0.71 USP2 (0.50) USP2NOS2CES1PLK4CHEK1
SCHEMBL2835871 0.71 PNMT (0.52) NOS2CES1MAOBPLK4CHEK1
SCHEMBL8195075 0.71 USP2 (0.42) USP2NOS2PLK4CHEK1AURKA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3798220-B1 P-PHENYLENEDIAMINE DERIVATIVE AS POTASSIUM CHANNEL REGULATOR AND PREPARATION METHOD AND MEDICAL APPLICATION THEREOF SHANGHAI ZHIMENG BIOPHARMA INC (CN) 2023-08-23 — — EP disclosed
CN-110511220-B P-diaminobenzene derivatives as potassium channel modulators, process for their preparation and their use in medicine 上海挚盟医药科技有限公司 2022-04-01 — — CN disclosed
EP-3798220-A1 P-PHENYLENEDIAMINE DERIVATIVE AS POTASSIUM CHANNEL REGULATOR AND PREPARATION METHOD AND MEDICAL APPLICATION THEREOF Shanghai Zhimeng Biopharma, Inc. (CN) 2021-03-31 — — EP disclosed
CN-112119079-A P-diaminobenzene derivatives as potassium channel modulators, process for their preparation and their use in medicine 上海挚盟医药科技有限公司 2020-12-22 — — CN disclosed
US-20150148334-A1 HETEROARYLS AND USES THEREOF MILLENNIUM PHARM INC (US) 2015-05-28 — — US disclosed
US-20150148334-A1 HETEROARYLS AND USES THEREOF MILLENNIUM PHARM INC (US) 2015-05-28 — — US disclosed
US-20150148334-A1 HETEROARYLS AND USES THEREOF MILLENNIUM PHARM INC (US) 2015-05-28 — — US disclosed
EP-2678328-B1 NOVEL CARBOXAMIDE MICROBIOCIDES SYNGENTA PARTICIPATIONS AG (CH) 2015-01-21 — — EP disclosed
US-8822523-B2 Carboxamide microbiocides SYNGENTA PARTICIPATIONS AG (CH) 2014-09-02 — — US disclosed
US-8822523-B2 Carboxamide microbiocides SYNGENTA PARTICIPATIONS AG (CH) 2014-09-02 — — US disclosed
US-20100004256-A1 HETEROARYL-FUSED MACROCYCLIC PYRIMIDINE DERIVATIVES ABBOTT LABORATORIES (US) 2010-01-07 — — US disclosed
WO-2009137492-A1 HETEROARYL-FUSED MACROCYCLIC PYRIMIDINE DERIVATIVES ABBOTT LABORATORIES (US) 2009-11-12 — — WO disclosed
EP-0927177-B1 NOVEL BENZOTHIOPHENE DERIVATIVES, THEIR PREPARATION AND USE AS UROKINASE INHIBITORS FUJISAWA PHARMACEUTICAL CO (JP) 2003-11-26 — — EP disclosed
US-6274619-B1 FUSED AMIDINO TYPE COMPOUNDS SUCH AS 4-(N-BUTYLCARBAMOYLMETHYLIDENE)-2-AMIDINO-4,5,6,7-TETRAHYDROBE NZO(B)THIOPHENE FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-08-14 — — US disclosed
US-6093710-A AN ENZYME INHIBITOR TREATING ANGIOGENESIS, ARTHRITIS, INFLAMMATION, METASTASIS, OSTEOPOROSIS, TUMORSANGIOGENESIS-DEPENDENT RETINOPATHIES, CONTRACEPTIVE FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2000-07-25 — — US disclosed
EP-0927177-A1 NOVEL BENZOTHIOPHENE DERIVATIVES, THEIR PREPARATION AND USE AS UROKINASE INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1999-07-07 — — EP disclosed
WO-1998011089-A1 NOVEL BENZOTHIOPHENE DERIVATIVES, THEIR PREPARATION AND USE AS UROKINASE INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1998-03-19 — — WO disclosed
US-4153611-A ANIMAL GROWTH REGULATORS AMERICAN CYANAMID COMPANY (US) 1979-05-08 — — US disclosed
US-4150035-A ANIMAL CROWTH REGULATORS AMERICAN CYANAMID COMPANY (US) 1979-04-17 — — US disclosed
US-4036979-A ANIMAL GROWTH RATE ACCELERATOR AMERICAN CYANAMID COMPANY (US) 1977-07-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150148334-A1 HETEROARYLS AND USES THEREOF RICTOR, AKT2, MTOR USP2 2806/4885NOS2 294/4885CES1 1338/4885
US-20100004256-A1 HETEROARYL-FUSED MACROCYCLIC PYRIMIDINE DERIVATIVES CDK2, DPYD, CCNB1 USP2 4655/4885NOS2 3707/4885CES1 813/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.